No. S 991
Infectious Diseases Act
(CHAPTER 137)
Infectious Diseases
(Mass Gathering Testing for
Coronavirus Disease 2019)
(Amendment No. 14) Regulations 2021
In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act, the Minister for Health makes the following Regulations:
Citation and commencement
1.  These Regulations are the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) (Amendment No. 14) Regulations 2021 and come into operation on 1 January 2022.
Amendment of regulation 1
2.  Regulation 1 of the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) Regulations 2021 (G.N. No. S 273/2021) (called in these Regulations the principal Regulations) is amended by deleting the words “Mass Gathering Testing for Coronavirus Disease 2019” and substituting the words “COVID‑19 Access Restrictions and Clearance”.
Amendment of regulation 2
3.  Regulation 2(1) of the principal Regulations is amended —
(a)by deleting paragraphs (b) and (c) of the definition of “cleared status” and substituting the following paragraphs:
“(b)a cleared status (special) that is current; or
(c)a cleared status (overseas temporary) that is current;”;
(b)by deleting the words “or (5), 7(2) or 7A(2), (3) or (4)” in the definition of “cleared status certificate” and substituting the words “, (5) or (5A), 7A(2), (3) or (4) or 7B(2)”;
(c)by deleting the definitions of “cleared status (general)” and “cleared status (limited)” and substituting the following definitions:
“ “cleared status (general)” has the meaning given by regulation 6;
“cleared status (overseas temporary)” has the meaning given by regulation 7B;”; and
(d)by inserting, immediately after the definition of “current”, the following definition:
“ “defined approved vaccine” means —
(a)Sinopharm COVID‑19 vaccine; or
(b)Sinovac‑Coronavac COVID‑19 vaccine;”.
Amendment of regulation 6
4.  Regulation 6 of the principal Regulations is amended —
(a)by deleting sub-paragraph (ii) of paragraph (2)(a) and substituting the following sub‑paragraph:
“(ii)ending on (and including) as follows:
(A)the 180th day after the date in sub‑paragraph (i), unless sub‑paragraph (B) applies;
(B)31 January 2022, where the individual is a transitional case; or”;
(b)by deleting sub-paragraph (ii) of paragraph (2)(b) and substituting the following sub‑paragraph:
“(ii)ending on (and including) as follows:
(A)the 180th day after the date in sub‑paragraph (i), unless sub‑paragraph (B) applies;
(B)31 January 2022, where the individual is a transitional case.”;
(c)by inserting, immediately after the words “Despite paragraph (2), (3) or (4)” in paragraph (5), the words “and except where expressly provided in paragraph (5A)”;
(d)by deleting the words “270th day” in paragraph (5)(d)(i) and substituting the words “180th day”;
(e)by inserting, immediately after paragraph (5), the following paragraph:
“(5A)  Where the Director is satisfied that an individual (of any age) —
(a)has received (whether before, on or after 1 January 2022) one dose of any defined approved vaccine and one dose of any other approved vaccine, each administered to the individual at least 17 days apart regardless of sequence;
(b)subsequently tests positive for SARS‑CoV‑2 upon undergoing (whether before, on or after 1 January 2022) any of the following:
(i)a polymerase chain reaction test in Singapore;
(ii)a polymerase chain reaction test outside Singapore, and a subsequent serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(c)is diagnosed (whether before, on or after 1 January 2022) as having had a COVID‑19 infection;
(d)is no longer actively infected with a COVID‑19 infection; and
(e)is without a cleared status (general), cleared status (special) or a cleared status (overseas temporary),
the Director may grant a certificate stating that the individual has a cleared status (general) for a period —
(f)starting the date the recovered individual first tested positive for SARS‑CoV‑2 upon undergoing a polymerase chain reaction test mentioned in sub‑paragraph (b) leading to the diagnosis of the individual having the last infection he or she recovered from; and
(g)ending on (and including) the 365th day after the date in sub‑paragraph (f).”;
(f)by deleting the words “or (5)” in paragraph (6)(a) and substituting the words “, (5) or (5A)”; and
(g)by inserting, immediately after paragraph (7), the following paragraph:
“(8)  An individual is a transitional case for the purposes of paragraph (2) —
(a)if he or she had acquired, before 1 January 2022, a cleared status (general) under paragraph (2), and would have continued on or after that date to have a cleared status (general) if not for the making of the Infectious Diseases (Mass Gathering Testing for Coronavirus Disease 2019) (Amendment No. 14) Regulations 2021; but
(b)not if he or she had acquired, before 1 January 2022, a cleared status (general) under paragraph (2) and ceased to have a cleared status (general) that is current before that date because of regulation 8A(1)(a) or (c).”.
Deletion of regulation 7
5.  Regulation 7 of the principal Regulations is deleted.
New regulation 7B
6.  The principal Regulations are amended by inserting, immediately after regulation 7A, the following regulation:
“Meaning of “cleared status (overseas temporary)”
7B.—(1)  For the purposes of these Regulations, an individual is treated as having a cleared status (overseas temporary) only if he or she is and to the extent certified under this regulation as having a cleared status (overseas temporary).
(2)  Where the Director is satisfied that an individual (of any age) arriving in Singapore on or after 1 January 2022 —
(a)is not ordinarily resident in Singapore;
(b)is without a cleared status (general) or cleared status (special); and
(c)has been administered (whether before, on or after 1 January 2022) an approved vaccine, or a combination of approved vaccines, in any way described in the First Schedule,
the Director may, in lieu of the period stated for those approved vaccines in the First Schedule, grant a certificate stating that the individual has a cleared status (overseas temporary) for a period —
(d)starting the time the individual arrives in Singapore; and
(e)ending on (and including) the 30th day after the day the individual arrives in Singapore.
(3)  The Director may cancel any certificate granted under this regulation stating that an individual has a cleared status (overseas temporary) if any of the following happens:
(a)before the end of the 30th day mentioned in paragraph (2)(e) which is applicable to the individual —
(i)the individual undergoes an approved test that is a polymerase chain reaction test; and
(ii)the individual’s test result shows the presence of SARS‑CoV‑2 in that individual and that is not an atypical finding for SARS‑CoV‑2;
(b)the individual is granted a cleared status (general);
(c)the Director is satisfied that it is the interest of the health and safety of the individual to do so.
(4)  To avoid doubt, the period in paragraph (2) may consist of a period before 1 January 2022.”.
Amendment of regulation 8A
7.  Regulation 8A of the principal Regulations is amended —
(a)by deleting the words “or (5)” wherever they appear in paragraph (2) and substituting in each case the words “, (5) or (5A)”;
(b)by deleting paragraph (3);
(c)by inserting, immediately after paragraph (3A), the following paragraph:
“(3B)  For the purposes of these Regulations, an individual who has a cleared status (overseas temporary) because he or she is granted a certificate under regulation 7B(2) does not have a cleared status (overseas temporary) that is current —
(a)after the end of the 30th day mentioned in and applicable to the individual under regulation 7B(2);
(b)during any suspended status interval, even if that interval lies within the period referred to in and applicable to the individual under regulation 7B(2); or
(c)after the cancellation under regulation 7B(3) of the certificate.”;
(d)by deleting the words “or (5), 7(2) or 7A(2), (3) or (4)” in paragraph (4) and substituting the words “, (5) or (5A), 7A(2), (3) or (4) or 7B(2)”; and
(e)by inserting, immediately after the words “of the Act” in paragraph (5)(c), the words “relating to COVID‑19”.
Deletion and substitution of regulation 13
8.  Regulation 13 of the principal Regulations is deleted and the following regulation substituted therefor:
“Cleared status requirement disapplied in certain cases
13.—(1)  Regulation 9(1) and (2) does not apply to or in relation to any of the following entrants:
(a)an entrant to a restricted place who is an uncleared junior;
(b)an entrant to a bar or a retail food and drinks establishment who —
(i)is a customer or visitor; and
(ii)collects food or drink from the bar or retail food and drinks establishment for consumption elsewhere not within the bar or retail food and drinks establishment.
(2)  Without affecting paragraph (1), regulations 9 and 10 do not apply to or in relation to an entrant to a restricted place during a restricted period of the restricted place if the entrant enters or remains in the restricted place —
(a)solely for any of the following purposes:
(i)to comply with an order or a direction given by or on behalf of a public officer or a public body in exercise of a power under any written law;
(ii)to preserve or protect the entrant or another individual’s life, health, or safety in an emergency; or
(b)in special circumstances connected with a particular live performance, sporting event or business event, where the risk to public health from disapplying regulations 9 and 10 to the entrant or entrants concerned is assessed by the Director as not of a substantial nature.”.
Amendment of First Schedule
9.—(1)  Item 1 of the First Schedule to the principal Regulations is amended —
(a)by deleting the words “365th day (including that day) after the start of the period.” in the fourth column relating to paragraph (2) and substituting the following paragraphs:
“(a)365th day (including that day) after the start of the period, unless paragraph (b) applies;
(b)120th day (including that day) after the start of the period where the other approved vaccine is a single dose of a defined approved vaccine.”; and
(b)by inserting, immediately after paragraph (5), the following paragraph:
“
First column
Second column
Third column
Fourth column
Approved vaccine
Vaccination
Start
End
 
(6)One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
”.
(2)  Item 2 of the First Schedule to the principal Regulations is amended —
(a)by deleting the words “365th day (including that day) after the start of the period.” in the fourth column relating to paragraph (2) and substituting the following paragraphs:
“(a)365th day (including that day) after the start of the period, unless paragraph (b) applies;
(b)120th day (including that day) after the start of the period where the other approved vaccine is a single dose of a defined approved vaccine.”; and
(b)by inserting, immediately after paragraph (5), the following paragraph:
“
First column
Second column
Third column
Fourth column
Approved vaccine
Vaccination
Start
End
 
(6)One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
”.
(3)  Item 3 of the First Schedule to the principal Regulations is amended —
(a)by deleting the words “365th day (including that day) after the start of the period.” in the fourth column relating to paragraph (2) and substituting the following paragraphs:
“(a)365th day (including that day) after the start of the period, unless paragraph (b) applies;
(b)120th day (including that day) after the start of the period where the other approved vaccine is a single dose of a defined approved vaccine.”; and
(b)by inserting, immediately after paragraph (5), the following paragraph:
“
First column
Second column
Third column
Fourth column
Approved vaccine
Vaccination
Start
End
 
(6)One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
”.
(4)  Item 5 of the First Schedule to the principal Regulations is amended —
(a)by deleting the words “365th day” in the fourth column relating to paragraphs (1), (2), (3), (4) and (5) and substituting in each case the words “120th day”; and
(b)by inserting, immediately after paragraph (5), the following paragraphs:
“
First column
Second column
Third column
Fourth column
Approved vaccine
Vaccination
Start
End
 
(6)Three doses of the defined approved vaccine opposite, administered at least 17 days apart for the first 2 doses and at least 86 days apart between the second and third doses.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(7)Two doses of the defined approved vaccine opposite administered at least 17 days apart, followed by a third dose either of Sinovac‑Coronavac COVID‑19 vaccine or another approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(8)One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a dose of a defined approved vaccine, where each dose is administered at least 17 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(9)One dose of the defined approved vaccine opposite, followed by a dose of Sinovac‑Coronavac COVID‑19 vaccine where each dose is administered at least 17 days apart, followed by a third dose of any approved vaccine, where the second and third doses are administered at least 86 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(10)Two doses of the defined approved vaccine opposite administered, at least 17 days apart to a recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(11)Two doses of the defined approved vaccine opposite administered at least 17 days apart, to a recovered individual after recovery from the COVID‑19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of “recovered individual” in regulation 2(1).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(12)One dose of the defined approved vaccine opposite, followed by a dose of Sinovac‑Coronavac COVID‑19 vaccine administered at least 17 days apart, to a recovered individual after recovery from the COVID‑19 infection, if he or she is a recovered individual mentioned in paragraph (10).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(13)One dose of the defined approved vaccine opposite, followed by a dose of Sinovac‑Coronavac COVID‑19 vaccine administered at least 17 days apart, to a recovered individual after recovery from the COVID‑19 infection, if he or she is a recovered individual mentioned in paragraph (11).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(14)At least 3 doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (6) to (13).
14th day after the last dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
”.
(5)  Item 6 of the First Schedule to the principal Regulations is amended —
(a)by deleting the words “365th day” in the fourth column relating to paragraphs (1), (2), (3), (4) and (5) and substituting in each case the words “120th day”; and
(b)by inserting, immediately after paragraph (5), the following paragraphs:
“
First column
Second column
Third column
Fourth column
Approved vaccine
Vaccination
Start
End
 
(6)Three doses of the defined approved vaccine opposite, administered at least 13 days apart for the first 2 doses and at least 86 days apart between the second and third doses.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(7)Two doses of the defined approved vaccine opposite administered at least 13 days apart, followed by a third dose either of Sinopharm COVID‑19 vaccine or another approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(8)One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a dose of a defined approved vaccine, where each dose is administered at least 17 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(9)One dose of the defined approved vaccine opposite, followed by a dose of Sinopharm COVID‑19 vaccine, where each dose is administered at least 17 days apart, followed by a third dose of any approved vaccine, where the second and third doses are administered at least 86 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(10)Two doses of the defined approved vaccine opposite administered, at least 13 days apart to a recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(11)Two doses of the defined approved vaccine opposite administered at least 13 days apart to a recovered individual after recovery from the COVID‑19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of “recovered individual” in regulation 2(1).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(12)One dose of the defined approved vaccine opposite, followed by a dose of Sinopharm COVID‑19 vaccine administered at least 17 days apart, to a recovered individual after recovery from the COVID‑19 infection, if he or she is a recovered individual mentioned in paragraph (10).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(13)One dose of the defined approved vaccine opposite, followed by a dose of Sinopharm COVID‑19 vaccine administered at least 17 days apart, to a recovered individual after recovery from the COVID‑19 infection, if he or she is a recovered individual mentioned in paragraph (11).
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(14)At least 3 doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (6) to (13).
14th day after the last dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
”.
(6)  Item 7 of the First Schedule to the principal Regulations is amended —
(a)by deleting the words “365th day (including that day) after the start of the period.” in the fourth column relating to paragraph (2) and substituting the following paragraphs:
“(a)365th day (including that day) after the start of the period, unless paragraph (b) applies;
(b)120th day (including that day) after the start of the period where the other approved vaccine is a single dose of a defined approved vaccine.”; and
(b)by inserting, immediately after paragraph (5), the following paragraph:
“
First column
Second column
Third column
Fourth column
Approved vaccine
Vaccination
Start
End
 
(6)One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
”.
(7)  The First Schedule to the principal Regulations is amended by inserting, immediately after item 7, the following item:
“
First column
Second column
Third column
Fourth column
Approved vaccine
Vaccination
Start
End
8.COVOVAX COVID‑19 vaccine or Nuvaxovid (Novavax COVID‑19 vaccine)
(1)Two doses, administered at least 17 days apart.
14th day after the second dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(2)One dose of the approved vaccine opposite, followed by a dose of another approved vaccine administered at least 17 days after the firstmentioned dose is administered.
14th day after the second dose is administered in accordance with the second column.
(a)365th day (including that day) after the start of the period, unless paragraph (b) applies;
(b)120th day (including that day) after the start of the period where the other approved vaccine is a single dose of a defined approved vaccine.
 
(3)One dose of the approved vaccine opposite, administered to a recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2, if he or she is a recovered individual because of having undergone a test or tests described in paragraph (a)(i) or (ii) of the definition of “recovered individual” in regulation 2(1).
14th day after the dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(4)One dose of the approved vaccine opposite, administered to a recovered individual after recovery from the COVID‑19 infection, if he or she is a recovered individual because of having undergone a test described in paragraph (a)(iii) of the definition of “recovered individual” in regulation 2(1).
14th day after the dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(5)Such number of doses and administered at such intervals as may be specified by the Director, where initial administration is not in accordance with paragraphs (1) to (4).
14th day after the last dose is administered in accordance with the second column.
365th day (including that day) after the start of the period.
 
(6)One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.
Upon the third dose being administered in accordance with the second column.
365th day (including that day) after the start of the period.
”.
[G.N. Nos. S 310/2021; S 324/2021; S 367/2021; S 396/2021; S 513/2021; S 542/2021; S 590/2021; S 620/2021; S 682/2021; S 768/2021; S 774/2021; S 863/2021; S 908/2021]
Made on 28 December 2021.
NG HOW YUE
Permanent Secretary
(Health Development),
Ministry of Health,
Singapore.
[AG/LEGIS/SL/137/2020/13 Vol. 4]
Singapore Statutes Online
© 2024 Attorney-General's Chambers of Singapore,
Last updated 27 Apr 2024
Singapore Statutes Online is provided by the Legislation Division of the Attorney-General's Chambers of Singapore.